- Home
- AGD vs TLSI Comparison
AGD vs TLSI Comparison
Compare AGD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGD | TLSI |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.7M | 274.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AGD | TLSI |
|---|---|---|
| Price | $12.42 | $5.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 61.2K | ★ 136.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,207,000.00 |
| Revenue This Year | N/A | $55.47 |
| Revenue Next Year | N/A | $40.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $8.20 | $3.42 |
| 52 Week High | $9.78 | $7.95 |
Technical Indicators
Market Signals| Indicator | AGD | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 33.53 |
| Support Level | $12.33 | $4.86 |
| Resistance Level | $12.60 | $5.87 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 50.57 | 9.52 |
Price Performance
Historical ComparisonAbout AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.